AZP-3404, an optimized peptide derived from IGFBP-2, improves glucose control in a preclinical model of severe insulin resistance through a new and unique mechanism of action
Lyon, France, March 21, 2019 – Alizé Pharma 3, a transatlantic company specialized in developing therapeutic peptides for the treatment of rare endocrine and metabolic diseases, today announces it will present preclinical results from its AZP-3404 program in syndromes of severe insulin resistance during the Annual Meeting of the Endocrine Society in New Orleans on March 23-26, 2019.
Key data, to be presented as an oral presentation, indicate that AZP-3404 induces dose-related improvement of glucose control in ob/ob mice, a model of severe insulin resistance and leptin deficiency. These results are supported by data on the mechanism through which AZP-3404 induces glucose uptake by muscle cells, which is in keeping with that of Insulin-like Growth Factor Binding Protein-2 (IGFBP-2).
Details of the oral presentation are as follows:
Abstract Number: 5410
Title: AZP-3404, a 9-Amino Acid Peptide Analog of Insulin-Like Growth Factor Binding Protein 2, Reverses Insulin Resistance in Leptin-Deficient ob/ob Mice
Session Number: OR05
Session Name: Diabetes: From Genetics to Novel Therapeutic Targets
Date and Time: Saturday, March 23, 2019, 11:30 AM – 1:00 PM CDT
Room: Ernest N. Morial Convention Center, Room 291
About AZP-3404, targeting syndromes of severe insulin resistance
AZP-3404 is the first compound to harness the biology of Insulin-like Growth Factor Binding Protein 2 (IGFBP-2), an endogenous protein with key physiological effects on glucose metabolism that are independent of its IGF-binding properties. Alizé Pharma 3 and its academic partners at the University of North Carolina at Chapel Hill and the University of Maine have identified and optimized short peptide fragments of IGFBP-2 that retain its biological activities. AZP-3404 is a stabilized analog of one of these IGFBP-2 fragments with an improved pharmacokinetic profile. As a result, AZP-3404 is highly potent in restoring glucose control preclinical models of severe insulin resistance. Based on its pharmacological profile, AZP-3404 is set to become a first-in-class treatment modality for syndromes of severe insulin resistance, that include a range of rare diseases associated with high mortality and morbidity.